Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

10.78 -0.23 (-2.13%)
Streaming Delayed Price Updated: 10:58 AM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
How Is The Market Feeling About ADMA Biologics? ↗
 
Via Benzinga
News headline image
Bull Run Alert: 3 Stocks Set to Soar in the Coming Months ↗
Get ready for the next bull run with these stocks. All three are showing impressive growth and massive returns. 
Via InvestorPlace
News headline image
Expert Ratings For ADMA Biologics ↗
 
Via Benzinga
News headline image
UroGen Pharma Stock Earns 91 RS Rating ↗
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
News headline image
Arcellx Stock Earns Relative Strength Rating Upgrade ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
News headline image
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights ↗
 
Via Benzinga
News headline image
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results ↗
 
Via Benzinga
News headline image
A Closer Look at 6 Analyst Recommendations For ADMA Biologics ↗
 
Via Benzinga
News headline image
Forecasting The Future: 4 Analyst Projections For ADMA Biologics ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
News headline image
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
News headline image
Krystal Biotech Stock Sees RS Rating Jump To 91 ↗
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
News headline image
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Recap: ADMA Biologics Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview For ADMA Biologics ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For ADMA Biologics ↗
 
Via Benzinga
News headline image
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024 ↗
ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Chart Of The Day: ADMA Biologics - Hitting New Highs ↗
100% technical buy signals 8 new highs and up 7.24% in the last month 110.10+ Weighted Alpha 
Via Talk Markets
News headline image
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces CFO Transition
Executive Search Initiated for CFO Replacement 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Conference Call Scheduled for February 28, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.